Imaging biomarkers in Parkinson's disease

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 614-628

  Brooks, David J ^a   Pavese, Nicola ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; MRI; Parkinson; PET; SPECT; Transcranial sonography

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE; DOPAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

AUTONOMIC DYSFUNCTION; BRAIN METABOLISM; CHOLINERGIC NERVE CELL; DEMENTIA; DEPRESSION; DIFFUSION TENSOR IMAGING; DOPAMINERGIC NERVE CELL; ECHOGRAPHY; FATIGUE; MONOAMINE NERVE CELL; MUSCLE RIGIDITY; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; TREMOR;

BIOLOGICAL MARKERS; BRAIN; BRAIN MAPPING; HUMANS; NEUROIMAGING; PARKINSON DISEASE; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 82755197075     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.08.009     Document Type: Review

References (173)

1. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
2. Ahlskog J.E. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003, 60:381-389.
3. 18F]fluorodeoxyglucose and PET. Mov. Disord. 1998, 13:268-274.
4. Antonini A., Leenders K.L., Vontobel P., Maguire R.P., Missimer J., Psylla M., Gunther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997, 120:2187-2195.
5. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of l-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994, 44:1325-1329.
6. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol. 1983, 61:101-108.
7. Asahina M., Suhara T., Shinotoh H., Inoue O., Suzuki K., Hattori T. Brain muscarinic recptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J. Neurol. Neurosurg. Psychiat. 1998, 65:155-163.
8. Austin M.C., Kalivas P.W. Enkephalinergic and GABAergic modulation of motor activity in the ventral pallidum. J. Pharmacol. Exp. Ther. 1990, 252:1370-1377.
9. Banati R.B., Newcombe J., Gunn R.N., Cagnin A., Turkheimer F., Heppner F., Price G., Wegner F., Giovannoni G., Miller D.H., Perkin G.D., Smith T., Hewson A.K., Bydder G., Kreutzberg G.W., Jones T., Cuzner M.L., Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123(Pt 11):2321-2337.
10. Benaderette S., Fregonara P.Z., Apartis E., Nguyen C., Trocello J.M., Remy P., Devaux J.Y., Askienazy S., Vidailhet M. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov. Disord. 2006, 21:310-317.
11. 123I]-FP-CIT Study Group. Mov. Disord. 2000, 15(May):503-510.
12. Berding G., Odin P., Brooks D.J., Nikkhah G., Matthies C., Peschel T., Shing M., Kolbe H., Van Den Hoff J., Fricke H., Dengler R., Samii M., Knapp W.H. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions With [F-18]FDG-PET. Mov. Disord. 2001, 16(November):1014-1022.
13. Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 2005, 20:383-385.
14. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., Tucha O., Preier M., Lange K.W., Reiners K., Gerlach M., Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 2002, 59:999-1005.
15. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 2001, 248:684-689.
16. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., Frey K.A. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J. Cereb. Blood Flow Metab. 2006, 26:1198-1212.
17. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., Mathis C.A., Moore R.Y., DeKosky S.T. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60:1745-1748.
18. Bohnen N.I., Muller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., Albin R.L. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73:1670-1676.
19. Braak H., Tredici K.D., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24(March):197-211.
20. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., De Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from novel positron emission tomography method. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2569-2574.
21. Brooks D.J. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol. 2003, 53:S110-S119.
22. Brooks D.J. Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wien. Klin. Wochenschr. 2006, 118:570-572.
23. Brooks D.J. Technology insight: imaging neurodegeneration in Parkinson's disease. Nat. Clin. Pract. Neurol. 2008, 4:267-277.
24. 11C-raclopride and PET. Ann. Neurol. 1992, 31:184-192.
25. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 1990, 28:547-555.
26. 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J. Neurol. Sci. 1999, 166:141-151.
27. Brundin P., Pogarel O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., El-Nagar G., Crabb L., Odin P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123:1380-1390.
28. Calon F., Dridi M., Hornykiewicz O., Bedard P.J., Rajput A.H., Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
29. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., Tomlinson B.E. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J. Neurol. Sci. 1983, 59:277-289.
30. 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov. Disord. 2004, 19:1175-1182.
31. Catalan M.J., Ishil K., Honda M., Samil A., Hallett M. A PET study of sequential finger movements of varying length in patients with Parkinson's disease. Brain 1999, 122:483-495.
32. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
33. de la Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., Lee C.S., Ruth T.J., Calne D.B., Stoessl A.J. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 2001, 49:298-303.
34. de la Fuente-Fernandez R., Schulzer M., Stoessl A.J. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol. Psychiatry 2004, 56:67-71.
35. 11C]raclopride PET study. Mov. Disord. 1999, 14:1025-1030.
36. 11C-WAY100635. Mov. Disord. 2000, 213.
37. Doder M., Rabiner E.A., Turjanski N., Lees A.J., Brooks D.J. Tremor in Parkinson's disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 2003, 60:601-605.
38. Eckert T., Barnes A., Dhawan V., Frucht S., Gordon M.F., Feigin A.S., Eidelberg D. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005, 26:912-921.
39. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat. Disord. 1998, 4:53-57.
40. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Chaly T., Robeson T., Margouleff D., Przedborski S., Fahn S. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 1994, 14:783-801.
41. Eisensehr I., Linke R., Noachtar S., Schwarz J., Gildehaus F.J., Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000, 123(Pt 6):1155-1160.
42. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003, 2:229-237.
43. Engberg T.M., Susel Z., Kuo S., et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 1991, 552:113-118.
44. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., Brooks D.J., Lees A.J., Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann. Neurol. 2006, 59:852-858.
45. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch. Neurol. 1999, 56:529-535.
46. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
47. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
48. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001, 57(December):2083-2088.
49. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., Dumouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344(March):710-719.
50. Fukuda M., Mentis M.J., Ma Y., Dhawan V., Antonini A., Lang A.E., Lozano A.M., Hammerstad J., Lyons K., Koller W.C., Moeller J.R., Eidelberg D. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001, 124:1601-1609.
51. Gaenslen A., Unmuth B., Godau J., Liepelt I., Di Santo A., Schweitzer K.J., Gasser T., Machulla H.J., Reimold M., Marek K., Berg D. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol. 2008, 7:417-424.
52. Geng D.Y., Li Y.X., Zee C.S. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 2006, 58:256-262. discussion 256-262.
53. Gerhard A., Banati R.B., Goerres G.B., Cagnin A., Myers R., Gunn R.N., Turkheimer F., Good C.D., Mathias C.J., Quinn N., Schwarz J., Brooks D.J. [(11)C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003, 61:686-689.
54. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21:404-412.
55. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 1992, 32:667-676.
56. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
57. Goerendt I.K., Messa C., Lawrence A.D., Grasby P.M., Piccini P., Brooks D.J. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 2003, 126:312-325.
58. Golbe L.I. The genetics of Parkinson's disease: a reconsideration. Neurology 1990, 40(Suppl. 3):7-16.
59. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., Houle S., Wilson A., Mundo E., Rusjan P., Meyer J., Kish S.J. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur. J. Neurol. 2007, 14:523-528.
60. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5(July):627-628.
61. Haslinger B., Erhard P., Kampfe N., Boecker H., Rummeny E., Schwaiger M., Conrad B., Ceballos-Baumann A.O. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001, 124(March):558-570.
62. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 1999, 56:179-187.
63. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., Jacobs A.H., Herholz K., Heiss W.D. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722.
64. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5976-5980.
65. 18FDG PET study. Brain 2000, 123:340-352.
66. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. The accuracy of the clinical diagnosis of Parkinson's disease: a clinicopathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 1992, 55:181-184.
67. Hughes A.J., Daniel S.E., Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001, 57:1497-1499.
68. Jahanshahi M., Jenkins I.H., Brown R.G., Marsden C.D., Passingham R.E., Brooks D.J. Self-initiated versus externally-triggered movements: measurements of regional cerebral blood flow and movement-related potentials in normals and Parkinson's disease. Brain 1995, 118:913-933.
69. Jellinger K. The pathology of parkinsonism. Movement Disorders 1987, vol. 2:124-165. Butterworths, London.
70. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:540-543.
71. Jenkins I.H., Fernandez W., Playford E.D., Lees A.J., Frackowiak R.S.J., Passingham R.E., Brooks D.J. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann. Neurol. 1992, 32:749-757.
72. Jenner P., Mori A., Hauser R., Morelli M., Fredholm B.B., Chen J.F. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:406-413.
73. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch. Neurol. 2004, 61:1224-1229.
74. Jolkkonen J., Jenner P., Marsden C.D. l-Dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 1995, 32:297-307.
75. Kaasinen V., Aalto S., Nagren K., Hietala J., Sonninen P., Rinne J.O. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J. Neural Transm. 2003, 110:591-601.
76. Kaasinen V., Nagren K., Hietala J., Oikonen V., Vilkman H., Farde L., Halldin C., Rinne J.O. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000, 54(April):1482-1487.
77. Kaasinen V., Nurmi E., Bergman J., Eskola O., Solin O., Sonninen P., Rinne J.O. Personality traits and brain dopaminergic function in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98(November):13272-13277.
78. Kaelin-Lang A., Liniger P., Probst A., Lauterburg T., Burgunder J.M. Adenosine A2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J. Neural Transm. 2000, 107:851-859.
79. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
80. 123I-beta-CIT SPECT. J. Nucl. Med. 2003, 44:870-876.
81. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 1988, 318:876-880.
82. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
83. Kishore A., De la Fuente-Fernández R., Snow B.J., Schulzer M., Mak E., Huser J., Stoessl A.J., Calne D.B. Levodopa-induced dyskinesias in idiopathic parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors. Neurology 1997, A327.
84. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., Brooks D.J., Bench C.J., Grasby P.M. Evidence for striatal dopamine release during a video game. Nature 1998, 393:266-268.
85. 18F]fluorodopa and positron emission tomography: error analysis and application to normal subjects. J. Cereb. Blood Flow Metab. 1993, 13:43-56.
86. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
87. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20(March):423-451.
88. Lawrence A.D., Brooks D.J. Neural correlates of reward processing in the human brain: a PET study. Neurology 1999, A307.
89. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
90. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J. Nucl. Med. 2004, 45:1688-1693.
91. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov. Disord. 2006, 21:510-514.
92. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 2005, 11:703-704.
93. Lozza C., Marie R.M., Baron J.C. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. Neuroimage 2002, 17:688-699.
94. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 2002, 52(November):628-634.
95. Mann D.M., Yates P.O. Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol. Appl. Neurobiol. 1983, 9:3-19.
96. Marshall V.L., Patterson J., Hadley D.M., Grosset K.A., Grosset D.G. Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Mov. Disord. 2006, 21:2247-2250.
97. Marshall V.L., Patterson J., Hadley D.M., Grosset K.A., Grosset D.G. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl. Med. Commun. 2006, 27:933-937.
98. 123I]FP-CIT SPECT. Mov. Disord. 2009, 24:500-508.
99. Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Edwards C., Mattis P., Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am. J. Psychiatry 2002, 159:746-754.
100. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 1979, 2:113-168.
101. 18F]dopa PET. J. Neurol. Neurosurg. Psychiat. 1998, 64:314-319.
102. 18F]dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 1995, 59:597-600.
103. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
104. Nicoletti G., Lodi R., Condino F., Tonon C., Fera F., Malucelli E., Manners D., Zappia M., Morgante L., Barone P., Barbiroli B., Quattrone A. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006, 129:2679-2687.
105. Nisbet A.P., Foster O.J.F., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger-RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995, 66:361-376.
106. 18F]CFT PET. Synapse 2003, 48:109-115.
107. 18F]fluoro-l-dopa PET study. Mov. Disord. 2001, 16(July):608-615.
108. Nurmi E., Ruottinen H.M., Kaasinen V., Bergman J., Haaparanta M., Solin O., Rinne J.O. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand. Ann. Neurol. 2000, 47(June):804-808.
109. Okamura N., Villemagne V., Drago J., Pejoska S., Dhamija R., Mulligan R., Ellis J., Ackermann U., O'Keefe G., Jones G., Kung H., Pontecorvo M., Skovronsky D., Rowe C. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J. Nucl. Med. 2010, 51:223-228.
110. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
111. 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J. Neurol. Sci. 1996, 136:169-173.
112. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57:168-175.
113. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123(Pt 9):1767-1783.
114. Pate B.D., Kawamata T., Yamada T., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 1993, 34:331-338.
115. Paulus W., Jellinger K. The neuropathological basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1991, 50:743-755.
116. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., Piccini P. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006, 67:1612-1617.
117. Pavese N., Khan N.L., Scherfler C., Cohen L., Brooks D.J., Wood N.W., Bhatia K.P., Quinn N.P., Lees A.J., Piccini P. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an (18)F-dopa PET progression study. Mov. Disord. 2009.
118. Pavese N., Metta V., Bose S.K., Chaudhuri K.R., Brooks D.J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133:3434-3443.
119. Paviour D.C., Price S.L., Jahanshahi M., Lees A.J., Fox N.C. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov. Disord. 2006, 21:989-996.
120. Paviour D.C., Thornton J.S., Lees A.J., Jager H.R. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov. Disord. 2007, 22:68-74.
121. Piccini P., Brooks D.J., Bjorklund A., Gunn R., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., Lindvall O. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
122. Piccini P., Burn D.J., Ceravalo R., Maraganore D.M., Brooks D.J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 1999, 45:577-582.
123. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., Oertel W., Quinn N., Samuel M., Rehncrona S., Widner H., Brooks D.J. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 2000, 48(November):689-695.
124. 18F-dopa PET study. Ann. Neurol. 1997, 41:222-229.
125. Piccini P., Pavese N., Brooks D.J. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann. Neurol. 2003, 53:647-653.
126. Piccini P., Pavese N., Hagell P., Reimer J., Bjorklund A., Oertel W.H., Quinn N.P., Brooks D.J., Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
127. Piccini P., Weeks R.A., Brooks D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 1997, 42:720-726.
128. Playford E.D., Jenkins I.H., Passingham R.E., Nutt J., Frackowiak R.S.J., Brooks D.J. Impaired mesial frontal and putamen activation in Parkinson's disease: a PET study. Ann. Neurol. 1992, 32:151-161.
129. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J. Neural Transm. 2005, 112:677-692.
130. Ponsen M.M., Stoffers D., Booij J., Van Eck-Smit B.L., Wolters E., Berendse H.W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 2004, 56:173-181.
131. 18F-dopa PET study. Brain 1999, 122.
132. Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine A(2A) receptor availability in Parkinson's disease patients with and without levodopa induced dyskinesias studied with C-11 SCH442416 PET. Neurology 2010, 74:A588.
133. Remy P., Doder M., Lees A.J., Turjanski N., Brooks D.J. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
134. 18F]fluorodopa uptake in five grafted parkinsonian patients. Ann. Neurol. 1995, 38:580-588.
135. Ribeiro M.J., Vidailhet M., Loc'h C., Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 2002, 59:580-586.
136. Rinne J.O., Laihinen A., Nagren K., Bergman J., Solin O., Haapparanta M., Ruotsalainen U., Rinne U.K. PET demonstrates different behaviour of striatal dopamine D1 and D2 receptors in early Parkinson's disease. J. Neurosci. Res. 1990, 27:494-499.
137. Rinne J.O., Laihinen A., Rinne U.K., Nagren K., Bergman J., Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov. Disord. 1993, 8:134-138.
138. Ruberg M., Rieger F., Villageois A., Bonnet A.M., Agid Y. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res. 1986, 362:83-91.
139. Sabatini U., Boulanouar K., Fabre N., Martin F., Carel C., Colonnese C., Bozzao L., Berry I., Montastruc J.L., Chollet F., Rascol O. Cortical motor reorganization in akinetic patients With Parkinson's disease-a functional MRI study. Brain 2000, 123(February):394-403.
140. Samuel M., Ceballos-Baumann A.O., Blin J., Uema T., Boecker H., Brooks D.J. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements: a PET study. Brain 1997, 120:963-976.
141. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
142. Sawle G.V., Playford E.D., Brooks D.J., Quinn N., Frackowiak R.S.J. Asymmetrical presynaptic and postsynaptic changes in the striatal dopamine projection in dopa-naive parkinsonism: diagnostic implications of the D2 receptor status. Brain 1993, 116:853-867.
143. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983, 275(September):321-328.
144. Scherfler C., Khan N.L., Pavese N., Lees A.J., Quinn N.P., Brooks D.J., Piccini P.P. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov. Disord. 2006, 21:783-788.
145. Schneider S.A., Edwards M.J., Mir P., Cordivari C., Hooker J., Dickson J., Quinn N., Bhatia K.P. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov. Disord. 2007, 22:2210-2215.
146. Schocke M.F., Seppi K., Esterhammer R., Kremser C., Jaschke W., Poewe W., Wenning G.K. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002, 58(February):575-580.
147. Schulz J.B., Skalej M., Wedekind D., Luft A.R., Abele M., Voigt K., Dichgans J., Klockgether T. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 1999, 45(January):65-74.
148. 11C-raclopride PET findings in patients with parkinsonism. Nucl. Med. Commun. 1994, 15:806-813.
149. Schweitzer K.J., Brussel T., Leitner P., Kruger R., Bauer P., Woitalla D., Tomiuk J., Gasser T., Berg D. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J. Neurol. 2007, 254:613-616.
150. Schwingenschuh P., Ruge D., Edwards M.J., Terranova C., Katschnig P., Carrillo F., Silveira-Moriyama L., Schneider S.A., Kagi G., Palomar F.J., Talelli P., Dickson J., Lees A.J., Quinn N., Mir P., Rothwell J.C., Bhatia K.P. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov. Disord. 2010, 25:560-569.
151. Seppi K., Schocke M.F., Esterhammer R., Kremser C., Brenneis C., Mueller J., Boesch S., Jaschke W., Poewe W., Wenning G.K. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003, 60(March):922-927.
152. Shannak K., Rajput A., Rozdilsky B., Kish S., Gilbert J., Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res. 1994, 639:33-41.
153. Shinotoh H., Inoue O., Hirayama K., Aotsuka A., Asahina M., Suhara T., Yamazaki T., Tateno Y. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J. Neurol. Neurosurg. Psychiat. 1993, 56:467-472.
154. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 1993, 34:324-330.
155. Sossi V., de la Fuente-Fernandez R., Holden J.E., Schulzer M., Ruth T.J., Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J. Cereb. Blood Flow Metab. 2004, 24:869-876.
156. Stiasny-Kolster K., Doerr Y., Moller J.C., Hoffken H., Behr T.M., Oertel W.H., Mayer G. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
157. Strafella A.P., Paus T., Fraraccio M., Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 2003, 126:2609-2615.
158. Svenningsson P., Hall H., Sedvall G., Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997, 27:322-335.
159. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999, 59:355-396.
160. Tagliavini F., Pilleri G., Bouras C., Constantinidis J. The basal nucleus of Meynert in idiopathic Parkinson's disease. Acta Neurol. Scand. 1984, 70:20-28.
161. Taylor M.D., De Ceballos M.L., Rose S., et al. Effects of unilateral 6-hydroxydopamine lesion and prolonged l-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol. 1992, 219:183-192.
162. 11C]raclopride displacement and PET. Neurology 1996, 46:1430-1436.
163. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., Stoessl A.J. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
164. Turjanski N., Lees A.J., Brooks D.J. PET studies on striatal dopaminergic receptor binding in drug naive and l-dopa treated Parkinson's disease patients with and without dyskinesia. Neurology 1997, 49:717-723.
165. Vaillancourt D.E., Spraker M.B., Prodoehl J., Abraham I., Corcos D.M., Zhou X.J., Comella C.L., Little D.M. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
166. Vingerhoets F.J.G., Schulzer M., Calne D.B., Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann. Neurol. 1997, 41(January):58-64.
167. Vingerhoets F.J.G., Snow B.J., Lee C.S., Schulzer M., Mak E., Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 1994, 36:759-764.
168. Walter U., Dressler D., Probst T., Wolters A., Abu-Mugheisib M., Wittstock M., Benecke R. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch. Neurol. 2007, 64:1635-1640.
169. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P.P., Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov. Disord. 2004, 19:1445-1449.
170. Wenning G.K., Odin P., Morrish P.K., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Brown R., Gustavii B., Hagell P., Jahanshahi M., Sawle G.V., Bjorklund A., Brooks D.J., Marsden C.D., Quinn N.P., Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disase. Ann. Neurol. 1997, 42:95-107.
171. 18F-dopa PET study. Ann. Neurol. 2003, 206-213.
172. Whone A.L., Watts R.L., Stoessl J., Davis M., David M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., Brooks D.J., Group F.T.R.-P.S. Slower progression of PD with ropinirol versus l-dopa: the REAL-PET study. Ann. Neurol. 2003, 54:93-101.
173. Yee R.E., Huang S.C., Stout D.B., Irwin I., Shoghi-Jadid K., Togaski D.M., DeLanney L.E., Langston J.W., Satyamurthy N., Farahani K.F., Phelps M.E., Barrio J.R. Nigrostriatal reduction of aromatic l-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J. Neurochem. 2000, 74(March):1147-1157.